CareDx, Inc.

CDNA

US14167L1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:31:23 2026-02-13 am EST			5-day change	1st Jan Change
19.90 ^USD	+4.16%		+2.90%	+6.34%

Feb. 12	CareDx, Inc. - Special Call
Feb. 12	Caredx, Inc. Announces Clinical Validation Results for Alloheme, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy	CI

CareDx, 10x Genomics Launch Platform to Study Transplant Rejection and Drug Response

Published on 01/07/2026 at 08:56 am EST

MT Newswires

Headlines

	Airbnb posts underwhelming results	05:54am
	AEP: data centre boom lifts profits	Feb. 12
	Moderna in a Spin After FDA Declines to Review Flu Vaccine Candidate	Feb. 11
	Thomson Reuters goes All-out on AI	Feb. 12
	Hermes International: Endurance over excitement	11:23am

Latest news about CareDx, Inc.

Feb. 12	CareDx, Inc. - Special Call
Feb. 12	Caredx, Inc. Announces Clinical Validation Results for Alloheme, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy	CI
Feb. 04	Aligos Therapeutics, Inc. Announces Management Changes	CI
Feb. 03	CareDx to Present AlloHeme Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings	CI
Jan. 23	CareDx Insider Sold Shares Worth $412,223, According to a Recent SEC Filing	MT
Jan. 12	Caredx Provides Earnings Guidance Fourth Quarter and Full Year 2025	CI
Jan. 12	NeoGenomics, Inc. Announces Chief Financial Officer Changes	CI
Jan. 12	NeoGenomics, Inc. Announces Executive Changes	CI
Jan. 12	CareDx Expects Increased Q4 Revenue and Better-Than-Expected Full-Year Revenue	MT
Jan. 07	CareDx, 10x Genomics Launch Platform to Study Transplant Rejection and Drug Response	MT
Jan. 07	CareDx, Inc. and 10x Genomics to Launch ImmuneScape - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response	CI
Dec. 18	CareDx provides notice of proposed derivative settlement	RE
Nov. 24	CareDx, Inc. Announces the Publication of the Third Manuscript from Surveillance HeartCare Outcomes Registry in the Journal of Heart and Lung Transplantation	CI
Nov. 07	Caredx announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Nov. 06	CareDx, Inc. Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025	CI

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâ€™s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.

Employees

647

Sector

Biotechnology & Medical Research

Calendar

Feb. 23 - Q4 2025 Earnings Release

More about the company